Apogee Therapeutics, Inc.
APGE
$70.02
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.96% | -100.59% | -98.34% | -116.88% | -109.90% |
| Total Depreciation and Amortization | 862.83% | 1,023.08% | 1,165.52% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 434.84% | 421.32% | 475.61% | 309.91% | -9.69% |
| Change in Net Operating Assets | -356.01% | -592.90% | -188.78% | -132.79% | -1.70% |
| Cash from Operations | -74.51% | -99.64% | -96.18% | -128.96% | -139.21% |
| Capital Expenditure | -285.15% | -925.48% | -888.03% | -589.82% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.67% | 99.35% | 29.07% | -9.34% | -64.46% |
| Cash from Investing | 140.21% | 98.12% | 27.61% | -9.69% | -65.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.39% | -93.93% | -94.08% | 56.92% | 42.87% |
| Repurchase of Common Stock | -- | -- | 29.58% | 29.58% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -85.37% | -93.94% | -94.10% | 56.98% | -7.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.87% | -200.32% | -209.91% | 170.53% | -134.69% |